Head and Neck Cancer and Immunotherapy with Dr. Nabil F. Saba

Dr. Nabil F. Saba, director of the head and neck oncology program at Winship Cancer Institute at Emory University, explains the use of new checkpoint inhibitors and other immunotherapies in head and neck cancer. #hncsm #CRIsummit #immunotherapy summit.cancerresearch.org/
00:00- Tamron Hall introduces Dr. Nabil Saba
00:37- Dr. Saba discusses head and neck cancer and immunotherapy
06:55- Arthur Brodsky leads a Q&A from the audience with Dr. Saba
Immunotherapy offers exciting new treatment options for patients with cancers of the mouth, throat, voice box, sinuses, nose, and salivary glands-especially those with HPV-positive cancers. Standard treatments have potentially devastating side effects for speaking, swallowing, and expression, so new options which preserve these functions are vital. www.cancerresearch.org/Immuno...
Questions from the audience for Dr. Saba:
- What are the promising clinical trials for head and neck cancers right now?
- Can immunotherapy be used to prevent cancer recurrence?
- Is immunotherapy now standard of care for patients who have HPV-related head and neck cancers?
- If you have HPV, are there ways you can prevent head and neck cancers from occurring?
- How long will I be followed after immunotherapy treatment? Are there any survivorship programs for cancer patients I should be aware of?
- Would you say immunotherapy is transforming the management of head and neck cancer or is it still in its beginning stages?
- Is it possible to use immunotherapy for other HPV-related cancers, i.e. anal, cervical, etc.?
- I am on surveillance. Should I consider immunotherapy to prevent reoccurrence?
- I have stage 4 head and neck cancer. I have been on Opdivo for 5 years and am NED. What happens if I stop treatment? If the tumors come back, can I restart treatment?
- There is a vaccine for preventing HPV cancer. Any value in having the vaccine after diagnosis of cancer?
Dr. Nabil Saba is a professor and vice chair for quality and safety at Emory University’s department of hematology and medical oncology and holds a joint appointment as a professor of otolaryngology at Emory University School of Medicine. He serves as the director of the head and neck oncology program and leads the head and neck working group at Winship Cancer Institute at Emory University. He is a recognized expert in head and neck cancer immunotherapy, focusing his work on translational research and the study and development of novel therapeutics in head and neck and esophageal cancer.
The 2021 CRI Virtual Immunotherapy Patient Summit is part of the Cancer Research Institute's Answer to Cancer Patient Education Program. It was offered free of charge, connecting cancer patients and caregivers with scientific and medical experts. This year’s Summit highlighted the growing implications of immunotherapy for more than 10 cancer types, provided education on the basics of immunotherapy and how clinical trials work, and addressed cancer care disparities. www.cancerresearch.org/en-us/...
Established in 1953, the Cancer Research Institute (CRI) is a 501(c)(3) nonprofit organization dedicated to harnessing our immune system’s power to control and potentially cure all cancers. Our mission: Save more lives by fueling the discovery and development of powerful immunotherapies for all types of cancer. To accomplish this, we rely on donor support and collaborative partnerships to fund and carry out the most innovative clinical and laboratory research around the world, support the next generation of the field’s leaders, and serve as the trusted source of information on immunotherapy for cancer patients and their caregivers. www.cancerresearch.org
Cancer Research Institute is a registered 501(c)(3) nonprofit under EIN 13-1837442. Donations are tax-deductible to the fullest extent allowable under the law.

[@joaoluizgomes4146]

Congratulations for the lecture.